Multifunctional iRGD–Pt–Iodine–W<sub>18</sub>O<sub>49</sub> Nanoparticles with Low Cisplatin-Induced Nephrotoxicity\nfor Gastric Cancer Theranostics

Multifunctional nanoparticles are able to achieve multiple\npurposes\nsuch as imaging and therapy simultaneously through modification with\nmultiple functional units and have significant advantages in cancer\ntheranostics. Among the multifunctional nanoparticles, W<sub>18</sub>O<sub>49</sub> NP-mediated multimodality theranostics are restricted\nby their undesirable tumor selectivity. In this study, we develop\nmultifunctional iRGD–Pt–Iodine–W<sub>18</sub>O<sub>49</sub> NPs (i–P–I–W) based on W<sub>18</sub>O<sub>49</sub> NPs, which integrates computed tomography\n(CT) imaging, PA imaging, chemotherapy, photodynamic therapy (PDT),\nand photothermal therapy (PTT) properties in a single targeting manner.\nDue to the presence of an iRGD peptide, tungsten, and iodine, these\niRGD–Pt–Iodine–W<sub>18</sub>O<sub>49</sub> NPs\nexhibit targeting contrasting ability for CT and PA imaging. Combined\nwith cisplatin, the iRGD–Pt–Iodine–W<sub>18</sub>O<sub>49</sub> NPs display remarkable targeting synergistic antitumor\neffects in vitro and in vivo. Meanwhile, iRGD–Pt–Iodine–W<sub>18</sub>O<sub>49</sub> NPs are capable of alleviating the cisplatin-induced\nnephrotoxicity at the administration dosage. Therefore, iRGD–Pt–Iodine–W<sub>18</sub>O<sub>49</sub> NPs are expected to be used in targeting CT/PA\ndual-imaging guided side effects relieving chemotherapy/PDT/PTT multimodality\nprecise therapy of gastric cancer.